{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.8","upperLimit":"9.8","value":"8.0"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"8","value":"7"},{"groupId":"OG002","lowerLimit":"6.5","upperLimit":"11","value":"7.8"},{"comment":"The upper level of the 95% Confidence Interval is not reached.","groupId":"OG003","lowerLimit":"6.1","upperLimit":"NA","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"PFS based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) defined per modified RECIST 1.1 for PM and iRECIST, or death, or is censored at time of last disease assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation\n\nStandard Chemotherapy: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.\n\nIpilimumab and Nivolumab: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population is comprised of intention-to-treat patients. One patient in the experimental arm of the Chemo Cohort was excluded due to a randomization error, with no treatment or follow-up data available.","reportingStatus":"POSTED","timeFrame":"Disease was evaluated at baseline, at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation). Median follow-up for survival is of 33 months with range (3 months - 47 months).","title":"Median Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}